title: Calcium acetate as a phosphorus binder in hemodialysis patients.
abstract: Much interest is currently centered on the use of calcium acetate as a phosphorus binder in patients with renal failure. Therefore, this compound in subjects previously stable on calcium carbonate and undergoing high-efficiency hemodialysis with a dialysate calcium of 2.5 mEq/L was evaluated. Twenty subjects were switched from generic calcium carbonate to a single calcium carbonate preparation for a period of 2 months. This was followed by a phase (1 month) in which calcium acetate was substituted for calcium carbonate at a dose containing half the amount of elemental calcium. Subjects then continued calcium acetate for 6 months. It was found that calcium acetate allowed comparable control of immunoreactive parathyroid hormone, calcium, and phosphorus levels compared with calcium carbonate. This occurred with half the amount of elemental calcium ingested in the form of calcium acetate (349 +/- 25 versus 699 +/- 75 mmol/day; P less than 0.001). With this lower dose, the overall incidence of hypercalcemia was the same with each formulation. In the eight subjects concurrently receiving i.v. calcitriol, the incidence of hypercalcemia was significantly higher during the first month of calcium acetate compared with that in those not receiving this compound (P less than 0.05). Of those four subjects receiving the high dose of calcitriol (2 micrograms thrice weekly), all required either reduction in the dose or discontinuation of the drug. Thus, mineral metabolism could be controlled adequately with calcium acetate despite using half as much elemental calcium compared with calcium carbonate. This, however, did not result in a lower incidence of hypercalcemia, particularly in those receiving i.v. calcitriol.
authors.affiliation: Renal Division, Washington University School of Medicine, St. Louis, MO.
authors.forename: J A
authors.initials: JA
authors.lastname: Delmez
authors.forename: C A
authors.initials: CA
authors.lastname: Tindira
authors.forename: D W
authors.initials: DW
authors.lastname: Windus
authors.forename: K Y
authors.initials: KY
authors.lastname: Norwood
authors.forename: K S
authors.initials: KS
authors.lastname: Giles
authors.forename: T L
authors.initials: TL
authors.lastname: Nighswander
authors.forename: E
authors.initials: E
authors.lastname: Slatopolsky
mesh_terms: D000085:Acetates / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D019342:Acetic Acid; D000328:Adult; D000368:Aged; D002117:Calcitriol / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood / Q000378:metabolism*; D006435:Renal Dialysis
chemical_list: D000085:Acetates; D010281:Parathyroid Hormone; D010758:Phosphorus; D002117:Calcitriol; D002119:Calcium Carbonate; D019342:Acetic Acid